HIV-1 drug resistance and genetic diversity in a cohort of people with HIV-1 in Nigeria. (1st January 2022)

• Record Type: Journal Article
• Authors: Oluniyi, Paul E.; Ajogbasile, Fehintola V.; Zhou, Shuntai; Fred-Akintunwa, Iyanuoluwa; Polyak, Christina S.; Ake, Julie A.; Tovanabutra, Sodsai; Iroezindu, Michael; Rolland, Morgane; Happi, Christian T.
• Is Part Of: AIDS. Volume 36:Number 1(2022)
• Publication Date: 2022-01-01
• Subjects: dolutegravir -- drug resistance -- HIV-1 -- primer ID -- subtype; AIDS (Disease) -- Periodicals; Acquired Immunodeficiency Syndrome; AIDS (Disease); Periodicals; Periodicals; 616.9792005
• DOI: 10.1097/QAD.0000000000003098
• Languages: English
• ISSNs: 0269-9370

Abstract

Abstract : Objective: This study was designed to provide information on the genetic diversity of HIV-1 and drug resistance mutations in Nigeria, as there is limited understanding of variants circulating in the country. Methods: We used an advanced next-generation sequencing platform, Primer ID, to: investigate the presence of high and low abundance drug resistance mutations; characterize preexisting Integrase Strand Transfer Inhibitor (INSTI) mutations in antiretroviral therapy (ART)-experienced but dolutegravir-naive individuals; detect recent HIV-1 infections and characterize subtype diversity from a cohort of people with HIV-1 (PWH). Results: HIV-1 subtype analysis revealed the predominance of CRF02_AG and subtype G in our study population. At detection sensitivity of 30% abundance, drug resistance mutations (DRMs) were identified in 3% of samples. At a sensitivity level of 10%, DRMs were identified in 27.3% of samples. We did not detect any major INSTI mutation associated with dolutegravir-resistance. Only one recent infection was detected in our study population. Conclusion: Our study suggests that dolutegravir-containing antiretroviral regimens will be effective in Nigeria. Our study also further emphasizes the high genetic diversity of HIV-1 in Nigeria and that CRF02_AG and subtype G are the dominant circulating forms of HIV-1 in Nigeria. These two circulating forms of the virus are largely driving the epidemic in the country. Abstract : Supplemental Digital Content is available in the text